Two for the price of one: Antibody drugs work by binding to antigens such as extracellular proteins or receptors on a cell's surface, blocking their ability to function or targeting them for ...

Scientists have uncovered a powerful new antibody that disrupts a key protein helping triple-negative breast cancer survive and evade immunity. Triple-negative breast cancer (TNBC) is considered one ...

A newly engineered antibody can penetrate kidney cysts and interrupt the growth signals that drive polycystic kidney disease.

New antibody therapy stopped tumor growth and blocked spread in treatment-resistant triple-negative breast cancer models.

Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant forms of breast cancer. It grows quickly, spreads early and lacks the hormone receptors that make other ...

Findings set the stage for further investigation of hSFRP2 mAb as a targeted therapy for triple-negative breast cancer.

The bispecific antibodies market offers promising opportunities due to its rising application in personalized medicine for cancers and autoimmune disorders, with significant growth in hematological ...

In its first bullet point in its release breaking down fourth quarter earnings, Regeneron said that sales of its coronavirus antibody treatment were $2.30 billion in the period, which represented a ...

On Tuesday, a Regeneron monoclonal antibody treatment site opened at the Downtown Jacksonville Main Library for people (12 and older) who have been exposed to COVID-19 or have recently tested positive ...